Idefirix Europeiska unionen - svenska - EMA (European Medicines Agency)

idefirix

hansa biopharma ab - imlifidase - desensitization, immunologic; kidney transplantation - immunsuppressiva - idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. the use of idefirix should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.

Locatim Sverige - svenska - Läkemedelsverket (Medical Products Agency)

locatim

biokema anstalt - immunglobulin g, bovint, anti immunglobulin g, bovint, anti-escherichia coli f5(k99)-adhesin, från kolostrum - oral lösning - nöt

Kinpeygo Europeiska unionen - svenska - EMA (European Medicines Agency)

kinpeygo

stada arzneimittel ag - budesonide, micronised - glomerulonephritis, iga - antidiarrheals, tarm -, antiinflammatoriska / antiinfective agenter - kinpeygo is indicated for the treatment of primary immunoglobulin a (iga) nephropathy (igan) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (upcr) ≥1. 5 g/gram.

Tecvayli Europeiska unionen - svenska - EMA (European Medicines Agency)

tecvayli

janssen-cilag international n.v. - teclistamab - multipelt myelom - antineoplastiska medel - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Talvey Europeiska unionen - svenska - EMA (European Medicines Agency)

talvey

janssen-cilag international n.v. - talquetamab - multipelt myelom - antineoplastiska medel - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Kloramfenikol Pharmathen 5 mg/ml Ögondroppar, lösning Sverige - svenska - Läkemedelsverket (Medical Products Agency)

kloramfenikol pharmathen 5 mg/ml ögondroppar, lösning

pharmathen s.a. - kloramfenikol - Ögondroppar, lösning - 5 mg/ml - borax hjälpämne; kloramfenikol 5 mg aktiv substans; borsyra hjälpämne

Oratoria 1 mg/ml Ögondroppar, lösning Sverige - svenska - Läkemedelsverket (Medical Products Agency)

oratoria 1 mg/ml ögondroppar, lösning

pharmathen s.a. - dexametasonnatriumfosfat - Ögondroppar, lösning - 1 mg/ml - dexametasonnatriumfosfat 1,093 mg aktiv substans

Cosopt sine 20 mg/ml + 5 mg/ml Ögondroppar, lösning Sverige - svenska - Läkemedelsverket (Medical Products Agency)

cosopt sine 20 mg/ml + 5 mg/ml ögondroppar, lösning

santen oy - dorzolamidhydroklorid; timololmaleat - Ögondroppar, lösning - 20 mg/ml + 5 mg/ml - timololmaleat 6,83 mg aktiv substans; dorzolamidhydroklorid 22,26 mg aktiv substans; mannitol hjälpämne

Cosopt sine 20 mg/ml + 5 mg/ml Ögondroppar, lösning Sverige - svenska - Läkemedelsverket (Medical Products Agency)

cosopt sine 20 mg/ml + 5 mg/ml ögondroppar, lösning

2care4 aps - dorzolamidhydroklorid; timololmaleat - Ögondroppar, lösning - 20 mg/ml + 5 mg/ml - dorzolamidhydroklorid 22,26 mg aktiv substans; timololmaleat 6,83 mg aktiv substans; mannitol hjälpämne

Cosopt sine 20 mg/ml + 5 mg/ml Ögondroppar, lösning Sverige - svenska - Läkemedelsverket (Medical Products Agency)

cosopt sine 20 mg/ml + 5 mg/ml ögondroppar, lösning

ebb medical ab - dorzolamidhydroklorid; timololmaleat - Ögondroppar, lösning - 20 mg/ml + 5 mg/ml - dorzolamidhydroklorid 22,26 mg aktiv substans; timololmaleat 6,83 mg aktiv substans; mannitol hjälpämne